To develop a new approach to the treatment of primitive neuroectodermal tumors we evaluated the eect of the HMG-CoA reductase inhibitor lovastatin on the Ewing's sarcoma cell line CHP-100. Lovastatin induced neural morphology and markers including neuron-speci®c enolase and neuro®lament protein. The acquisition of neural morphology required new mRNA synthesis, and cDNA microarray analysis con®rmed that lovastatin altered the program of gene expression. After morphologic dierentiation the cells underwent rapidly progressive apoptosis. In normal development of neuronal progenitors, dierentiation signals trigger p21 WAF1 accumulation, RB hypophosphorylation, enhanced RB ± E2F-1 association, and G1 arrest, and these events have been shown to protect from apoptosis. In contrast, in the Ewing's sarcoma cells lovastatin triggered dierentiation without causing cell cycle arrest: p21
Introduction
Peripheral primitive neuroectodermal tumors are part of a family of childhood tumors that includes Ewing's sarcoma. These tumors are collectively referred to as the Ewing's sarcoma family of tumors (ESFT) and are characterized by a rearrangement between the EWS gene and one of ®ve ETS-related transcription factors (for review see Kovar, 1998) , resulting in the formation of a chimeric transcription factor. The predominant fusion protein, EWS ± FLI1, has been shown to function as an aberrant transcription factor (May et al., 1993a,b) , and both EWS ± FLI1 and the variant chimeric protein EWS ± ETV1 activate common signaling pathways and promote oncogenesis (Thompson et al., 1999) . These tumors are thought to be derived from primitive neural progenitor cells, and retain the potential for neural dierentiation in vitro and in vivo (Lipinski et al., 1987; Tsokos, 1992) . Multimodality therapy has dramatically improved the prognosis of patients with localized disease (Fontaine et al., 1997) . In contrast, the prognosis is still poor for patients with locally recurrent or metastatic disease (Horowitz et al., 1993; JuÈ rgens, 1994; Ladenstein et al., 1995; Hense et al., 1999) .
Recently it has become apparent that normal neural progenitor cells are particularly vulnerable to apoptosis at the time of dierentiation, and that terminal withdrawal from the cell cycle is a key to survival during this period (for review see Lipinski and Jacks, 1999) . As might be expected from its role in G1-S transition, the retinoblastoma protein (RB) is critically important in achieving the required cell cycle withdrawal. RB knock-out mice die between day 13 and day 15 of gestation, with profound defects in neural, erythroid and lens development. In these lineages, early dierentiation is initiated, but late dierentiation markers do not develop. A failure to achieve cell cycle arrest and elevated levels of apoptosis are seen in the central and peripheral nervous system of RB7/7 mice.
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG ± CoA) reductase inhibitor lovastatin has been shown to induce reversible G1 synchronization in a wide array of normal and tumor cell lines (JaÂ kobisiak et al., 1991; Keyomarsi et al., 1991; Gudas et al., 1993; Munro et al., 1994; Gray-Bablin et al., 1997) . Lovastatin, which is widely prescribed for the treatment of hypercholesterolemia (Ross et al., 1999) , has been studied as an anti-cancer drug in a phase I clinical trial in the National Cancer Institute (Thibault et al., 1996) , and lovastatin alone or in combination with radiation treatment has been tested in phase II studies of astrocytoma and glioblastoma multiforme (Larner et al., 1998) . In addition, lovastatin has been shown to have anti-tumor activity against a variety of neoplasms including medulloblastoma (Macaulay et al., 1999) and neuroblastoma (Maltese et al., 1985) .
In the study presented here we have examined the eect of lovastatin on the human ESFT cell line CHP-100. We observed that lovastatin rapidly induced neural morphology, and this eect required new mRNA synthesis. Although the cells initiated dierentiation they unexpectedly continued to progress through the cell cycle. Examination of the cell cycle machinery revealed that there was a failure to induce p21 WAF1 and p27 KIP1 and there was a selective inactivation of RB in lovastatin-treated CHP-100 cells. These data present a new model for the study of dierentiation and apoptosis in ESFT.
Results
Effect of lovastatin on CHP-100 morphology CHP-100 cells consist of at least two morphologically distinct cell types ± a small round cell and a large, substratum-adherent¯at cell with abundant cytoplasm (Figure 1a , Whitesell et al., 1991) . After addition of 1 mM lovastatin to CHP-100 cells, features of neural morphology were easily detectable within 8 h (data not shown). Twenty-four hours after addition of lovastatin the treated cells had a uniformly neural appearance, characterized by bipolar or multipolar cells with small cell bodies, dendritic processes, and long branching processes with beaded varicosities (Figure 1b,c) . Lovastatin blocks the production of mevalonic acid from HMG ± CoA. Addition of excess mevalonate at the time of lovastatin addition completely reversed the eect of lovastatin on CHP-100 morphology and survival (data not shown), suggesting that the target for lovastatin action in the ESFT cells is in the HMG ± CoA reductase pathway.
Immunocytochemistry
Immunocytochemistry was used to evaluate the expression of neural markers in untreated and lovastatin-treated cells. The markers chosen for these studies were the 68, 160 and 200 kDa neuro®lament triplet proteins, neuron-speci®c enolase (NSE), and chromogranin B. The neuro®lament triplet proteins are neural tissue-speci®c cytoskeletal proteins that have been reported to be absent in undierentiated Ewing's sarcoma but present after neural dierentiation (Cavazzana et al., 1987) . As shown in Table 1 , lovastatin induced 68 kDa neuro®lament triplet immunoreactivity. Expression of the 160 and 200 kDa components of the neuro®lament triplet proteins did not increase. Among the neuro®lament triplet proteins, the 68 kDa form is the ®rst component expressed in neural dierentiation (Pachter and Leim, 1984) . Therefore the expression pattern of the neuro®lament triplet proteins in lovastatin-treated CHP-100 cells is characteristic of an early stage of neural dierentiation. The neural-associated glycolytic enzyme NSE, which also has been shown to be absent in undierentiated Ewing's sarcoma cell lines but induced when these cells undergo neural dierentiation (Cavazzana et al., 1987) , was induced by lovastatin (Table 1) . Chromogranin B, an acidic protein present in chroman granules and a marker of neuroendocrine tissues and their tumors (Tsokos, 1992) was not induced by lovastatin ( Table 1 ).
As will be described later, neural dierentiation of the CHP-100 cells is followed immediately by apoptosis. It is therefore dicult to obtain a clear cytochemical image of neural marker induction. In a previous report, Bernal et al. (1983) made separate clones of the two predominant morphologies, which they labeled CHP-100-S for small refractile cells, and CHP-100-L for large¯at cells. When we tested these monotypic cultures we found that unlike the parental polymorphic culture, the CHP-100-S cells had constitutive expression of some neural markers, while the CHP-100-L cells were negative (data not shown). Lovastatin was cytotoxic to both cell types. Unexpectedly, it was the CHP-100-L cells which responded to lovastatin by cell body rounding, extensive process formation, and induction of neural markers. Because the induction of apoptosis by lovastatin occurs more slowly in these cells than in the parental culture it was possible to obtain a micrograph of neural marker induction. As shown in Figure 2 , lovastatin induced 68 kDa neuro®lament protein and neuron-speci®c enolase in the CHP-100-L cells.
Change in gene expression induced by lovastatin
To test whether the induction of neural morphology required new mRNA synthesis we incubated CHP-100 cells with both lovastatin and the RNA polymerase II inhibitor actinomycin D and compared their morphology to cells incubated with lovastatin alone. Actinomycin D blocked the appearance of neural morphology in response to lovastatin ( Figure 3 ). These data suggest that the induction of neural dierentiation by lovastatin requires new gene expression. Therefore we examined the eect of lovastatin on gene expression in CHP-100 cells by comparison of cDNA microarrays hybridized with¯uorescent cDNAs generated from RNAs isolated from control CHP-100 cells and cells incubated with 1 mM lovastatin for 24 h. Consistent with the eect of actinomycin D on lovastatin-treated cells, lovastatin markedly modulated gene expression in the CHP-100 cells. Of the 2026 cDNA and ESTs examined, lovastatin induced greater than twofold upregulation in nine discrete mRNAs, and greater than twofold downregulation in 172 discrete mRNAs (data not shown).
Cell cycle analysis
Normal neural progenitors withdraw from the cell cycle at the time of dierentiation. To continue our comparison of the lovastatin-treated CHP-100 cells with normal dierentiating neural cells, we examined the cell cycle phase distribution of exponentially growing CHP-100 cells to cells treated with lovastatin (Table 2) . Twenty-four hours after addition of 1 or 2 mM lovastatin the cells failed to show cell cycle phasespeci®c synchronization. Treatment with 2 mM lovastatin produced a marked increase in the percentage of cells with hypodiploid DNA content, consistent with the induction of apoptosis (Nicoletti et al., 1991) . Consistent with a lack of cell cycle arrest, the mitotic index of control cells was 3% and the mitotic index in cells treated with lovastatin for 24 h was 5%.
Induction of apoptosis by lovastatin
CHP-100 cells began displaying morphologic changes characteristic of apoptosis within 24 h following addition of lovastatin. Large membrane blebs became a prominent feature of the plasma membrane ( Figure  1c ). Ultrastructural studies showed signi®cant apoptotic changes consisting of nuclear chromatin margination, cytoplasmic blebbing and condensation, and nuclear membrane disruption in virtually all of the cells by 24 h after addition of lovastatin ( Figure 1d ). In the culture treated with lovastatin, apoptosis was also con®rmed by DNA condensation and fragmentation, visualized by DNA staining with DAPI ( Figure 4a ). Furthermore, internucleosomal chromatin fragmentation, resulting in a ladder of nucleosome monomer and oligomers, a hallmark of apoptosis (Wyllie, 1980) , was also induced in the CHP-100 cells treated with lovastatin ( Figure 4b ). During apoptosis, poly ADPribose polymerase (PARP) is cleaved to yield two fragments, a large molecular weight fragment of 89 kd, and a small fragment of 24 kd (Nicholson et al., 1995) . As shown in Figure 4c , both large and small molecular weight PARP cleavage products were detected in the lysate of lovastatin-treated CHP-100 cells. Thus lovastatin induces apoptosis in CHP-100 cells as assessed by a variety of criteria, including hypodiploid DNA content determined by¯ow cytometry, agarose 
Analysis of cell cycle-regulatory proteins
Because lovastatin did not induce cell cycle arrest we examined the eect of lovastatin on the status of proteins critical for the G1/S phase transition. There was no detectable eect of lovastatin on the level of cyclin D1, cyclin E, cdk2, cdk4 or cdk6 (Figure 5a ). In addition there was no inhibition of either cyclin E-or cdk2-associated kinase activity in response to lovastatin ( Figure 5b ). These data suggested that RB protein might continue to be phosphorylated in lovastatintreated cells. As shown in Figure 5c , the level of RB protein decreased in lovastatin-treated cells, and hypophosphorylated RB markedly declined. The loss of hypophosphorylated RB and continued cyclin Eand cdk2-associated kinase activity suggested that the RB protein that persisted was phosphorylated. To test this, recombinant GST ± RB protein was incubated with immunoprecipitated cyclin E-associated kinase in an immune complex kinase reaction. The ability of cyclin E-associated kinase to phosphorylate RB was unabated in lovastatin-treated cells (Figure 5d ). We have reported previously that lovastatin induces p21 WAF1 protein, RB hypophosphorylation, enhanced RB-E2F-1 association and growth arrest in prostate cancer cells (Lee et al., 1998) . In contrast, p21 WAF1 protein was not induced in lovastatin-treated CHP-100 cells (Figure 5c ), consistent with the continued cyclin E-associated kinase activity. Lovastatin has also been reported to increase protein expression of the related cdk inhibitor p27 KIP1 (Hengst et al., 1994) . Western blot analysis of p27 levels in control and lovastatin-treated cells showed that there was abundant p27 expression in the presence or absence of lovastatin (Figure 5c ). The robust cyclin E-and cdk2-associated kinase activity and the rapid growth rate of the untreated CHP-100 cells (less than 24 h doubling time, data not shown) in the presence of high levels of p27 protein, suggest a possible defect in the cyclin/cdk/cdk inhibitor pathway in these ESFT cells.
We tested if the ability of RB to associate with E2F-1 was compromised in response to lovastatin. There was a decreased but detectable level of E2F-1 in lovastatin-treated versus control cells (Figure 5c ). Consistent with the absence of growth arrest, coimmunoprecipitation analysis demonstrated that there was a striking loss of RB ± E2F-1 association in lovastatin-treated cells (Figure 5e ).
Elevation of p21 WAF1 attenuates lovastatin-induced apoptosis
The data presented thus far suggested that the failure to induce p21 WAF1 or growth arrest was facilitating apoptosis in response to lovastatin. To test this hypothesis we infected CHP-100 cells with a control adenovirus (Ad ± LacZ) and an adenovirus expressing wild type p21 WAF1 (Ad ± p21
WAF1
). As shown in the viral 
Discussion
There has been renewed interest in dierentiation therapy for the treatment of cancer, in part due to the success of retinoic acid treatment for acute promyelocytic leukemia (Kogan and Bishop, 1999) , and the promise of histone deacetylase inhibitors that also act as dierentiating agents (Richon et al., 1998) . Retinoic acid directly targets the aberrant transcriptional repression activity of the oncogenic fusion protein in acute promyelocytic leukemia. Although the oncogenic fusion proteins resulting from the EWS ± ETS gene rearrangement have been identi®ed in ESFT, it has not as yet been possible to speci®cally target these proteins in vivo.
The histogenesis of ESFT suggests a potential vulnerability that might be exploited therapeutically. The ESFT are undierentiated small-round-cell tumors, representing pluripotent cells or neural progenitors, with the potential for neural dierentiation.
Normal neuronal progenitors are particularly vulnerable to apoptosis when they are in the early stages of dierentiation. These observations suggest that an agent that induces dierentiation in ESFT cells may facilitate apoptosis. It is also known, however, that activation of RB and exit from the cell cycle protects the normal dierentiating neuronal progenitor. Thus, a traditional dierentiating agent that induces the cdk inhibitor p21 WAF1 and RB hypophosphorylation would be expected to induce exit from the cell cycle. In contrast, an agent that induces dierentiation without induction of p21 WAF1 and RB activation might be expected to induce apoptosis. The data presented here demonstrate that in the ESFT cell line CHP-100, the HMG ± CoA reductase inhibitor lovastatin ful®lls these criteria, and is a potent inducer of apoptosis.
The data presented here demonstrate a novel model for studying ESFT and for analysis of the molecular determinants regulating dierentiation and apoptosis in peripheral primitive neuroectodermal cells. Lovastatin induced neural morphology and markers of neural dierentiation, and shortly after the appearance of the dierentiated phenotype the cells underwent apoptosis. The initial event in this process, the appearance of neural morphology, was dependent on new mRNA synthesis. Consistent with that, lovastatin altered the gene expression pro®le of the CHP-100 cells, as detected by cDNA microarray analysis. The 11 : 22 reciprocal translocation is detectable on a molecular level in CHP-100 cells and in greater than 90% of ESFT. It juxtaposes EWS, a gene of unknown function, with FLI, a member of the ETS transcription factor family. The new chimeric protein EWS ± FLI acts as a dominant oncogene and an aberrant Total cell lysates were prepared and Western blot analysis was performed using anti-cyclin D1, anti-cyclin E, anti-Cdk2, anti-Cdk4, or anti-Cdk6 antibody and ECL detection. (b) Eect of lovastatin on cyclin E-associated kinase and Cdk2 kinase activity. Cells were treated with lovastatin (1 mM), cell lysates were immunoprecipitated with anti-cyclin E or Cdk2 antibody and kinase activity was assayed using histone H1 as a substrate. (c) Cells were treated with 1 mM lovastatin for the time indicated. Total cell lysates were prepared and Western blot analysis was performed using anti-RB, anti-hypophospho RB, anti-E2F1, anti-p21 WAF1 , or anti-p27 KIP1 antibodies and ECL detection. (d) Eect of lovastatin on cyclin E-associated kinase activity. Cells were treated with lovastatin (1 mM), cell lysates were immunoprecipitated with anti-cyclin E antibody and kinase activity was assayed using GST ± RB as a substrate. (e) Total cell lysates (2 mg protein) from control cells and cells incubated with 1 mM lovastatin for 24 h were immunoprecipitated with anti-E2F-1 antibody. Immune complexes were separated by SDS-polyacrylamide gels, transferred to nitrocellulose and probed with anti-pRB antibody. Proteins were detected by ECL transcription factor (Bailly et al., 1994; Denny, 1996) . We have analysed control and lovastatin-treated CHP-100 cells for expression of the EWS ± FLI fusion transcript by nested PCR, and we did not observe down-regulation of EWS ± FLI expression after 24 h incubation with 1 mM lovastatin (data not shown). Thus, lovastatin may not be aecting survival of the ESFT cells by reducing expression of EWS ± FLI. Among the mRNAs signi®cantly induced by lovastatin there were the neural marker S-100 and the proliferation-associated gene c-jun (data not shown). Further analysis of the gene expression pro®le may aid in dissection of the mechanisms associated with dierentiation and apoptosis/survival in neural progenitor tumor cells.
Lovastatin has been shown to induce a non-toxic G1 arrest in a variety of cell types, and there have been several reports of lovastatin-induced G1 arrest in tumor cells. Unexpectedly, lovastatin had no eect on the cell cycle distribution in CHP-100 cells. We and others have demonstrated that lovastatin-induced G1 arrest in other cell types is associated with induction of the cdk inhibitor p21 WAF1 (Lee et al., 1998; Muller et al., 1999) . As shown here, however, lovastatin did not induce both p21 WAF1 and p27 KIP1 in the CHP-100 cells. Consistent with this, there was no inhibition of cdk2- or cyclin E-associated kinase activity, RB remained hyperphosphorylated, and E2F-1 association with RB was markedly reduced. Free E2F-1 has two wellcharacterized activities; facilitation of cell cycle progression (for review see Dyson, 1998) and induction of apoptosis (Field et al., 1996; Shan et al., 1996; Yamasaki et al., 1996; DeGregori et al., 1997; Phillips et al., 1997) . Both events are seen in response to lovastatin, suggesting that the release of free E2F-1 may play a role in lovastatin-induced apoptosis. It has been demonstrated that E2F-1 can inhibit antiapoptotic signals and that loss of RB can confer sensitivity to E2F-1-mediated apoptosis (Phillips et al., 1999) . Deregulation of E2F-1 and other critical cell cycle regulatory proteins is a common feature of many tumor cells (Kastan et al., 1995; Hall and Peters, 1996) and may be a factor in the enhanced sensitivity of certain tumor cells to cytotoxic chemotherapy (Kaelin, 1999; Phillips et al., 1999; Shapiro and Harper, 1999) . The utilization of E2F-1 as a therapeutic strategy was demonstrated in a recent article in which oligopeptides designed to inactivate cyclin A/cdk2 and activate E2F-1-induced apoptosis had tumor-speci®c cytotoxic activity (Chen et al., 1999; Commentary: Lees and Weinberg, 1999) . In the data presented here, overexpression of p21 WAF1 protected the cells against lovastatin-induced cytotoxicity. Protection by p21 WAF1 from chemotherapy-induced apoptosis has been demonstrated previously in several cell types (Polyak et al., 1996; Stewart et al., 1999; Blagosklonny et al., 2000) . The failure to induce p21 WAF1 and activate RB in response to lovastatin in the Ewing's cells, and the partial rescue from cell death by overexpression of p21 WAF1 suggest that an aberrant G1 checkpoint response contributes to the mechanism of apoptosis in the lovastatin-treated CHP-100 cells.
The data presented here indicate that CHP-100 cells, although undierentiated in morphology and phenotype, can be induced to undergo neural dierentiation and subsequent apoptosis within 24 h after addition of lovastatin. This system, therefore, may be a useful model for identifying the signal transduction pathways regulating decisions of cell fate in a primitive neural progenitor tumor and for the development of a new therapeutic approach to the treatment of patients with advanced ESFT.
Materials and methods

Cell culture
The Ewing's sarcoma cell line CHP-100 (Schlesinger et al., 1976) was obtained from Dr A Evans, Children's Hospital of Philadelphia. The CHP-100-L and CHP-100-S cell lines were obtained from Dr Stephen Baylin, Johns Hopkins Oncology Center (Bernal et al., 1983) . The cells were maintained as a monolayer culture in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum, penicillin, streptomycin and amphotericin (Bio¯uids, Gaithersburg, MD, USA).
Materials
Lovastatin was kindly provided by AW Alberts (Merck, Sharp and Dohme Research Pharmaceuticals, Rahway, NJ, USA). Monoclonal antibodies to 68, 160 and 200 kDa neuro®lament protein and chromogranin B were purchased from Boehringer Mannheim (Indianapolis, IN, USA) . Monoclonal antibodies to NSE was purchased from Biomedia (Foster City, CA, USA) and monoclonal anti-PARP and anti-p53 antibodies were from Calbiochem (La Jolla, CA, USA). Polyclonal antibodies to cyclin E, Cdk2, Cdk4, Cdk6, and monoclonal anti-E2F-1 (clone 20) were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Monoclonal antibodies to RB (clone G3-245), hypophosphorylated RB (clone G99-549), p21
WAF1
, and p27 KIP1 were purchased from PharMingen (San Diego, CA, USA). Anti-p53 antibody Ad-LacZ, a b-galactosidase expressing, replication de®cient, adenovirus was generous gifts from Dr Bert Vogelstein (Johns Hopkins University). Ad-p21 WAF1 was obtained from Dr WS El-Deiry (Univ. Pennsylvania, Philadelphia, USA) and viral titer was determined as previously described (Blagosklonny et al., 1997) . The multiplicity of infection (MOI) was de®ned as the ratio of the total number of plaque forming units (PFU) used in a particular infection divided by the number of cells.
Immunocytochemistry
Cells were grown on sterile coverslips, ®xed with 3.7% formaldehyde in phosphate-buered saline (PBS) for 10 min and permeabilized with 0.2% Triton X-100 for 10 min at room temperature (Jang et al., 1999) . Nonspeci®c binding sites were blocked by incubating the cells with 1% bovine serum albumin in PBS for 1 h at 48C. Primary antibody was added to the coverslip and incubated for 1 h at 48C. The coverslip was washed two times for 2 min each with PBS and incubated at 48C for 1 h with Cy3-conjugated goat antimouse immunoglobulin (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). After incubation, the coverslip was washed with PBS, rinsed quickly with water, air dried, and mounted onto a glass slide using SlowFade (Molecular Probes, Eugene, OR, USA).
Electron microscopy
For scanning electron microscopy, the cells were ®xed in situ with glutaraldehyde, dehydrated, critical-point dried, coated with gold palladium, and examined in an Amray 1820 scanning electron microscope. For transmission electron microscopy, the cells were ®xed in 2.5% glutaraldehyde, post®xed in 1% osmium tetroxide, dehydrated in graded alcohols and propylene oxide, and embedded in Maraglas 655 (Ladd Research Industries, Burlington, VT, USA). Ultrathin sections of selected areas were stained with uranyl acetatelead citrate and examined in a Philips CM10 electron microscope.
Flow cytometry, mitotic index and DNA synthesis
Exponentially growing cells were compared to cells treated with lovastatin for 24 h. Cells were harvested, ®xed in 70% ethanol and incubated with RNase A and the DNAintercalating dye propidium iodide. Cell cycle phase analysis was performed as described previously (Lee et al., 1998) . The mitotic index was determined by staining control and lovastatin-treated cells with 4,6-diamidino-2-phenylindole (DAPI; Sigma, St. Louis, MO, USA), visually inspecting 200 cells, using a Zeiss Axiophot¯uorescence microscope and the 63X objective, and determining the number of cells in mitosis per 100 cells examined. DNA synthesis was monitored by 3 H-thymidine incorporation as described previously (Blagosklonny et al., 1997) . In brief, 20 000 cells were plated in 24-well plates. The next day, cells were infected with indicated MOI of Ad-p21 WAF1 or Ad-LacZ for 24 h and then were incubated with 1 mCi [methyl
Apoptosis analysis
For DAPI staining, cells were washed two times with PBS and ®xed with 3.7% formaldehyde in PBS for 10 min at room temperature. Fixed cells were washed two times with PBS, and DAPI was added and allowed to incubate for 10 min at room temperature. The cells were washed two more times with PBS. Coverslips were mounted on glass slides and analysed by¯uorescence microscopy using a Zeiss Axiophot microscope. Fragmentation of DNA was determined by the method of Ishizawa et al. (1991) with the following modi®cation. Cells were washed with PBS and resuspended in lysis buer (1 mM EDTA, 10 mM Tris (pH 8.0), 1% SDS, 1 mg/ml proteinase K). After 1 h incubation at 378C, RNase A was added and incubation continued for a further 1 h. Crude DNA preparations were extracted twice with phenol : chloroform : isoamyl alcohol (25 : 24 : 1) and electrophoresed at 120 V on a 0.8% agarose gel containing ethidium bromide (EtBr; Sigma), examined on an ultraviolet light source and photographed.
Immunoprecipitation and Western blot analysis
Immunoprecipitations were performed as described (Bang et al., 1994) . Cell lysates were incubated with anti-cyclin E, antiCdk2 polyclonal antibody or anti-E2F-1 monoclonal antibody. The immunocomplex was collected on protein ASepharose (Sigma) and analysed by SDS-polyacrylamide gel electrophoresis. For Western blot analysis, cells were washed in PBS and lysed with TNN lysis buer (40 mM Tris (pH 8.0), 120 mM NaCl, 0.5% NP-40, 0.1 mM sodium orthovanadate, 2 mg/ml aprotinin, 2 mg/ml leupeptin and 100 mg/ml PMSF) at 48C for 20 min. Lysates were spun at 14 000 r.p.m. for 15 min to remove cellular debris. Protein concentrations were determined with the BCA reagent (Pierce, Rockford, IL, USA). Equal amounts of protein were subjected to electrophoresis on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes (Schleicher & Schuell, Keene, NH, USA) by electroblotting. After extensive washing with 10 mM Tris, pH 7.5, 50 mM NaCl and 2.5 mM EDTA, the blots were incubated with horseradish peroxidaseconjugated secondary antibody, and speci®c protein bands were visualized with an enhanced chemiluminescence detection system (ECL; Amersham).
Immune complex kinase assay
Immune complex kinase assays were performed as described (Bang et al., 1994) . Brie¯y, cell lysates were incubated with primary antibody, and immune complexes were collected on protein A-Sepharose beads and resuspended in kinase assay mixture containing 3 mCi of [g-32 P]ATP (ICN, Costa Mesa, CA, USA) and histone H1 (Life Technologies Inc.) and GST ± RB (Kaelin et al., 1991) as a substrate. After 1 h incubation, the beads were incubated in lysis buer and the proteins were separated on 10% SDS ± polyacrylamide gels and bands were detected by autoradiography.
Abbreviations ESFT, Ewing's sarcoma family tumors; RB, retinoblastoma protein; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; NSE, neuron-speci®c enolase; PARP, poly ADPribose polymerase; EST, expressed sequence tag; MOI, multiplicity of infection.
